Search

Displaying results 6541 - 6550 of 8411 in total
  1. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  2. Drug

    Trefentanil

    go.drugbank.com/drugs/DB09181
    Experimental

    Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.

  3. Drug

    Aftobetin

    go.drugbank.com/drugs/DB20425
    Investigational

    Aftobetin has a monoisotopic molecular weight of 452.23 Da.

  4. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe has a monoisotopic molecular weight of 809.43 Da.

  5. Drug

    Salacetamide

    go.drugbank.com/drugs/DB20217
    Investigational

    Salacetamide has a monoisotopic molecular weight of 179.06 Da.

  6. Drug

    Irampanel

    go.drugbank.com/drugs/DB21123
    Investigational

    Irampanel has a monoisotopic molecular weight of 309.15 Da.

  7. Drug

    Azilsartan mopivabil

    go.drugbank.com/drugs/DB21569
    Experimental

    Azilsartan mopivabil has a monoisotopic molecular weight of 676.25 Da.

  8. Drug

    Taragarestrant

    go.drugbank.com/drugs/DB21574
    Investigational

    Taragarestrant has a monoisotopic molecular weight of 474.13 Da. … Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).

    Synonyms: D 0502
  9. Drug

    Riselcaftor

    go.drugbank.com/drugs/DB21685
    Experimental

    Riselcaftor has a monoisotopic molecular weight of 516.17 Da.

  10. Drug

    Barnidipine

    go.drugbank.com/drugs/DB09227
    Investigational

    Barnidipine contains two chiral centres thus can have four possible enantiomers. … study in patients with mild to moderate hypertension, the antihypertensive response from barnidipine treatment was maintained after a 1-year and 2-year follow-up period in 91% of the patients who had an

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors